TY - JOUR T1 - Effects of Sarilumab on Patient-Reported Impact of Rheumatoid Arthritis Using the Rheumatoid Arthritis Impact of Disease Scale JF - The Journal of Rheumatology JO - J Rheumatol DO - 10.3899/jrheum.180904 SP - jrheum.180904 AU - Laure Gossec AU - Vibeke Strand AU - Clare Proudfoot AU - Chieh-I Chen AU - Sophie Guillonneau AU - Toshio Kimura AU - Hubert van Hoogstraten AU - Erin Mangan AU - Matthew Reaney Y1 - 2019/03/15 UR - http://www.jrheum.org/content/early/2019/06/07/jrheum.180904.abstract N2 - Objective The impact of rheumatoid arthritis (RA) symptoms on patients’ lives is significant. This study evaluated the effect of sarilumab on patient-perceived impact of RA using the 7-domain RA Impact of Disease (RAID) scale. Methods Two phase III, randomized, controlled trials of sarilumab in patients with active, long-standing RA were analyzed: sarilumab 150 mg and 200 mg twice-weekly plus conventional synthetic disease-modifying antirheumatic drugs (+csDMARDs) versus placebo+csDMARDs [TARGET (NCT01709578)]; sarilumab 200 mg versus adalimumab 40 mg monotherapy (MONARCH [NCT02332590]). Least squares mean (LSM) differences in RAID total score (range 0–10), and 7 key RA symptoms, including pain and fatigue (baseline to weeks 12 and 24), were compared. ‘Responders’ by RAID total score were defined by improvements from baseline ≥Minimal Clinically Important Difference (MCID), and ≥Patient Acceptable Symptom State (PASS) at end point. Results Sarilumab 150 mg and 200 mg+csDMARDs were nominally superior (p<0.05) versus placebo+csDMARDs and 200 mg versus adalimumab 40 mg in LSM differences for RAID total score at weeks 12 (–0.93 and –1.13; –0.49, respectively) and 24 (–0.75 and –1.01; –0.78), and all impacts of RA (except functional impairment in MONARCH week 12). Effects were greater in physical domains (e.g., pain) than mental domains (e.g., emotional well-being). More patients receiving sarilumab versus placebo or adalimumab reported improvements ≥MCID and PASS in total RAID scores at both assessments. Conclusion Based on the RAID, sarilumab+csDMARDs or as monotherapy reduced the impact of RA on patients’ lives to a greater extent than placebo+csDMARDs or adalimumab monotherapy. ER -